CDER approved 50 novel drugs in 2024, record number of biosimilars
Regulatory NewsJeff Craven
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesCDERExpedited pathwaysOrphan drugsPharmaceuticalsProduct LifecycleSubmission and registrationUnited StatesUS Food and Drug Administration (FDA)